October 15, 2025 2:15 PM ET
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Chris Markoch
Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments
NYSE:NVONYSE:LLYNASDAQ:SEPN